Latest news with #RxT17
The Print
2 days ago
- Business
- The Print
Renalyx Health Systems to invest Rs 800 cr for setting up 3 dialysis machine production units
Currently, the company manufactures RxT 17 through contract manufacturing and with the launch of RxT 21, it will set up its own facilities at Bengaluru and Mysuru in Karnataka and at Mumbai in Maharashtra, Renalyx Health Systems Founder and Director Shyam Vasudeva Rao told PTI. RENALYX – RxT 21 machine is world's first fully indigenous, AI and cloud-enabled smart hemodialysis machine with real-time remote monitoring and clinical connectivity facility, the company said. Mumbai, Jun 11 (PTI) Bengaluru-headquartered Renalyx Health Systems on Wednesday said it is planning to invest Rs 800 crore in the next four years to set up three manufacturing units to produce RENALYX – RxT 21 machine that will help dialysis affordable and accessible to a larger population. This is expected to raise the manpower of the company to over 500 people in 1-2 years from the current 100, he added. 'RxT 21 makes Renalyx the sixth company globally and first in India to produce an advanced dialysis machine with EU CE certification, a mandatory conformity marking for products sold within the European Economic Area (EEA). We are aiming for an annual capacity of 5,000 machines in the company-owned manufacturing units,' he added. The Indian CDSCO (Central Drugs Standard Control Organisation) approval of the machine is in its final stages and is expected by July this year, while the US FDA approval process is underway and anticipated by March 2026, he said. When asked how the company is planning to raise Rs 800 crore for setting up the manufacturing units, Rao said, the company will get it through a mix of foreign direct investment (FDIs), equity and debt. 'The company plans to raise funds through the sale of equity, backed by strong interest from prominent Indian and international investors. In addition, it will raise debt, and the promoters will also invest capital. We are also planning to go public within the next three years,' he added. Renalyx Health Systems is a technology innovation company which is focused on delivering inclusive solutions for comprehensive renal care. With initial deployments of the machine planned in Maharashtra and Karnataka, the company will go for rapid pan-India distribution of RxT 21 with its partners as well as exports to other countries. Rao said the company has penetrated international markets, and has secured orders from South Africa, the USA, and Europe. In India, Renalyx plans to install RxT 21 at primary health centres (PHC), community health centres (CHC), private dialysis centres and hospitals to make renal care available to a large number of people. PTI SM HVA This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
&w=3840&q=100)
Business Standard
3 days ago
- Business
- Business Standard
Renalyx launches smart dialysis unit RxT21, plans ₹800 crore boost
Bengaluru-based Renalyx Health Systems has launched a cloud-enabled and AI-powered smart haemodialysis machine with real-time remote monitoring and clinical connectivity. Named RxT21 and priced at ₹6.7 lakh, the machine is claimed to be significantly cheaper than imported alternatives. Comparable models in the market cost 20–25 per cent more, the company said. Renalyx plans to invest ₹800 crore over the next four years to build manufacturing capacity for an initial 5,000 RxT21 machines by FY26, with an additional 1,500-unit capacity by FY28. The company will also manufacture consumables indigenously. Renalyx has manufacturing facilities in Bengaluru and Mysuru in Karnataka and in Mumbai, Maharashtra, to support its scale-up plans and meet rising demand. CDSCO approval for the RxT21 is in its final stages and expected by July 2025, while the USFDA approval process is under way and anticipated by March 2026, the company told Business Standard. Shyam Vasudeva Rao, founder and director of Renalyx Health Systems, said RxT21 would bring dialysis closer to patients' homes, helping reduce dropout rates. Remote monitoring is critical, especially as many rural patients miss their dialysis sessions—typically three per week—due to travel challenges. 'With this machine, we can monitor a patient's vitals during dialysis and stop the process immediately if any issue arises, reducing the need for highly trained manpower at rural centres,' Rao said. According to data from the Pradhan Mantri National Dialysis Programme (PMNDP), approximately 220,000 new cases of end-stage renal disease (ESRD) are reported in India annually, generating demand for 34 million dialysis sessions. Industry estimates suggest the country currently performs 21–22 million sessions annually, supported by 50,000 dialysis machines, 5,000 centres, and about 3,000 practising nephrologists. As the dialysis sector grows, domestic medical device makers are entering the fray. Currently, most dialysis machines in India are imported, with German firm Fresenius leading the market. Industry estimates indicate that 35,000 of the 50,000 machines deployed in India are from Fresenius. These machines typically cost between ₹7–8 lakh, excluding the cost of dialysers (the filtering unit) and other consumables. Founded in 2012, Renalyx also produces the RxT17 dialysis machine, which has standard features. It has licensed Bharat Electronics (BEL) to manufacture 6,000 RxT17 units over the next three years. The company has invested ₹52 crore so far in manufacturing and R&D. 'The company plans to raise funds through equity sales, supported by strong interest from Indian and international investors. In addition, it will raise debt, with promoters also infusing capital. Renalyx intends to go public within the next three years,' it said in a statement. Initial deployments of the RxT21 are planned in Maharashtra and Karnataka. Renalyx will then pursue rapid pan-India distribution of the machine in partnership with domestic collaborators and also export to global markets. The company has already secured orders from South Africa, the United States, and Europe.
